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Introduction: Focal seizures represent the most common seizure type and focal epilepsies the 
most common epilepsy type. Anti-seizure medications (ASMs) still represent the main form of 
treatment for epilepsy.  
Areas covered: The aim of this review article is to provide an overview of available evidence 
about current and upcoming pharmacological options and strategies for adults with focal 
epilepsy focusing on the last 5 years. 
Expert opinion: Seventeen drugs are currently approved for the treatment of focal seizures 
including cenobamate as the very latest option. Ten of these drugs are also licensed for 
monotherapy. Level A evidence for initial monotherapy is available for seven drugs with no 
robust data supporting that one drug is superior to the other. Safety, tolerability as well as 
pharmacoeconomic reasons would then drive treatment decisions. Data on adjunctive treatment 
are available for 13 ASMs showing again no obvious difference in terms of efficacy. Evidence 
on specific drug combinations is almost non-existent and the final decision of combining 
specific drugs is based on the experience of the individual clinician rather than on robust 
evidence. Current outcome measures do not consider number of previously failed drugs and 














Epilepsy is a serious neurological disorder affecting over 70 million people worldwide with 
incidence rates around 50 (40-70) per 100,000 per year in high income countries and above 80-
100 per 100,000 per year in low income countries [1]. Epilepsy poses a substantial economic 
burden for health systems, individuals and their families [2]. Focal seizures represent the most 
common seizure type and focal epilepsies the most common epilepsy type [3]. 
Antiseizure medications (ASMs) still represent the main form of treatment for epilepsy 
including focal epilepsies. The number of ASMs currently available is now becoming large 
and some debate has started on their classification in terms of generation. In this paper, the 
distinction into two generations of compounds has been adopted following Perucca et al. 2020 
[4]. This distinction is mainly based on the chronological order these drugs have been marketed 
and those introduced after 1989 are generally referred to as second-generation drugs [4]. The 
development of these second generation ASM was aimed at addressing the shortcomings of 
older, first-generation drugs (barbiturates, benzodiazepines, carbamazepine, ethosuximide, 
phenytoin, and valproic acid), such as their unfavourable pharmacokinetics and drug 
interaction profiles, ineffectiveness in controlling the seizures, and propensity to induce many 
adverse effects [4]. Despite some of these drugs have shown some advantages in terms of 
pharmacokinetics, potential for interactions and tolerability [5], the proportion of drug-resistant 
patients remains dramatically unchanged and patients on polytherapy still present with often 
unacceptable medication-related side effects [6].  
Treatment outcome studies in epilepsy have shown that one third of patients are controlled on 
a single ASM, another third requires a combination of two or more drugs to be seizure free, 
while, in the remaining third, chances of becoming seizure free are considerably low and these 
patients have uncontrolled seizures lifelong [7]. The definition of drug-resistance proposed by 
the International League Against Epilepsy (ILAE) has introduced the concept of sustained 
seizure freedom which represents the only efficacy outcome measure consistently associated 
with improved quality of life [8]. Using this measure, a systematic review and meta-analysis 
of placebo-controlled studies of ASMs has pointed out that the overall pooled-risk difference 
in favour of new ASMs compared with placebo is only 6% (95% CI 4%-8%) with a number 
needed to treat (NNT) of 16 [9]. A prospective trial of adults with drug-resistant focal epilepsy 
pointed out that less than 1 in 10 patients with drug resistant focal epilepsy achieve seizure 
freedom on a newly introduced ASM and provided validated estimates of seizure freedom 
according to number of previously failed trials ranging from 12% after two failed drugs to <3% 
after at least six failures [10].   
The aim of this review article is to provide an overview of available evidence about current 
and upcoming pharmacological options and strategies for adults with focal epilepsy focusing 
on the last 5 years. References were identified by searches of Medline/PubMed and the 
Cochrane library for human studies published in English between June 30th, 2015, and June 
30th, 2020, with the search terms: (seizure* OR epilepsy) AND (focal) AND (treatment*) AND 
(mono* OR adjunc* OR add*) AND outcome. This search generated 211 abstracts. Articles 
were selected based on originality and relevance to the present topic. Additional references 
were identified from the author’s own files and from chosen bibliographies. A total of 63 papers 
have been included in this article. 
 
2. CURRENT PHARMACOLOGICAL OPTIONS AND STRATEGIES: AN 




Around 60% to 70% of people with epilepsy will achieve a long term remission from seizures 
[11] and many of them on a single ASM (monotherapy). Of the 17 drugs currently licensed for 
focal seizures, 10 have a monotherapy indication by either the Food and Drug Administration 
(FDA) or the European Medicine Agency (EMA) (Table 1). The ILAE Subcommission on 
ASM Guidelines published a systematic review in 2013, including 64 comparative randomized 
controlled trials (RCTs) and 11 meta-analyses, undertaken between 1940 and 2012 [12]. This 
document showed that Level A of evidence [13] for initial monotherapy for adults with focal 
epilepsy is available for levetiracetam (LEV), zonisamide (ZNS), controlled-release 
carbamazepine (CBZ-CR) and phenytoin (PHT) as all these drugs have Class 1 studies; 
lamotrigine (LTG) and gabapentin (GBP) have class I studies in elderly (≥60 years) adults with 
focal epilepsy  [12].  
Since then, Level A of evidence supported by Class 1 studies became available for lacosamide 
(LCM) and eslicarbazepine acetate (ESL) [14,15], subsequently confirmed by a network meta-
analysis [16]; while, regarding elderly patients, class 1 RCT on LEV [17] added this compound 
to the list of drugs with a Level A of evidence. A subsequent meta-analysis suggested that LTG, 
LEV, and GBP have even higher efficacy than CBZ-CR in elderly people [18]. A network 
meta-analysis showed that despite the lack of significant differences in efficacy across 
treatments, LCM, LTG, and LEV have the highest probability of ranking best for achieving 
seizure freedom in elderly people. CBZ and CBZ-CR showed a poor tolerability profile, 
leading to higher withdrawal rates when compared to LEV and VPA [19]. 
A meta-analysis of RCTs of PHT and valproate (VPA) monotherapy involving 669 patients 
showed no  difference in 12 months seizure freedom between the two drugs but this meta-
analysis  included a heterogeneous group of subjects with focal and generalised seizures [20]. 
Limited and very low-certainty evidence support the use of clonazepam (CLN) in monotherapy 
for the treatment of epilepsy [21]. No difference in efficacy and tolerability was found in a 
small trial comparing CLN to CBZ for the treatment of mesial temporal lobe epilepsy but over 
all data do not support the use of CLN in monotherapy for newly diagnosed patients. 
 
Current pharmacotherapy of epilepsy consists of orderly, sequential drug trials, in which ASMs 
are chosen under the concept of individual patient-oriented (or -tailored) pharmacotherapy. It 
is, therefore, evident, that if data on efficacy show that LEV, LTG, ZNS, LCM, PHT and CBZ-
CR are equally effective [4], data on tolerability may then guide therapeutic strategies. 
However, a network analysis of monotherapy studies showed that all these options seem to be 
equally tolerated and just CBZ (immediate release) seems to be burdened by lower tolerability 
as compared to other compounds especially LTG [22]. In this context, individualised treatment 
strategies considering comorbidities, patient’s preference and pharmacoeconomic reasons are 
often adopted. 
Safety of ASMs is another important parameter that may guide treatment decisions. Among 
drugs licensed for the treatment of focal seizures in adults, vigabatrin and retigabine are known 
to have serious safety concerns. Vigabatrin was approved for focal seizures in 1989 and after 
around 10 years, the drug was associated with irreversible visual field defects [23]. Since then, 
vigabatrin has been used mostly as an orphan drug used in infantile spasms. Retigabine was 
approved in 2011 for focal seizures but two years later the FDA issued a warning for blue 
discoloration of the skin, eyes, and retina pigmentation which led to the drug being withdrawn 
from the market in 2017 [24].   
Malformation risk is another important aspect regarding safety of ASMs. It is established that 
exposure to VPA in utero is associated with a lower intelligence quotient [25] as well as an 
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increased risk of developing autism spectrum disorder [26] as compared to unexposed children. 
However, data from the EURAP register have also showed that CBZ-CR > 700 mg is 
associated with an increased risk of malformations as compared to LTG≤325 mg and LEV 
[27]. As a consequence prescription patterns in women with epilepsy have changed 
substantially during the past two decades [28], with a substantial increase in the use of LTG 
and LEV who are widely considered first choice in women of childbearing age. 
 
2.2 Adjunctive treatment 
When monotherapy fails, adjunctive treatment represents a potential option. Given the number 
of ASMs the number of combinations is substantial, and each combination has both advantages 
and disadvantages, which are different and variable related to individual case scenarios. 
Mechanism of action is often considered when combining drugs although robust evidence 
supporting specific combined treatment is almost non-existent. The combination VPA and 
LTG is often mentioned as an example of a favourable pharmacodynamic interaction. 
However, in focal epilepsies, evidence is based on an unblind randomised, 60-week superiority 
trial in 207 patients with focal and generalised seizures that showed that VPA-LTG is as 
effective as CBZ-CR [29].  
Meta-analyses on efficacy and safety of individual ASMs as adjunctive treatment are available 
for 13 compounds (Table 2). All these drugs have shown very similar response rates, meaning 
at least 50% seizure reduction, while data on withdrawal risk seems to favour LTG, LEV, GBP 
and BRV.  
LTG and LEV showed to be effective and well tolerated representing the best choice again in 
adjunctive treatment [30,31]. Psychiatric side effects in predisposed patients should be 
considered especially for LEV [32]. The use of OXC is based on low quality findings and safety 
data suggest a high risk of treatment withdrawal due to side effects [33]. LCM seems to be 
effective and well tolerated but not at high doses (>400 mg per day) [34]. Perampanel (PRP) 
seems to be effective from 4 mg but data on seizure response suggest minimum benefits from 
high doses (>10 mg) [35]. Data on GBP suggest a minimum effective dose 900 mg per day 
with a target dose of 1800 mg [36] while for tiagabine (TGB) the optimal dose seems to be 
around 30 mg per day [37]. Despite meta-analyses do not seem to disfavour TGB, the 
association with cases of status epilepticus [38] made this drug less and less popular. There are 
three trials comparing pregabalin (PGB) to LTG, LEV and GBP, showing that PGB has higher 
response rates than LTG (RR 1.47; 95%CI 1.03-2.12) but not higher than LEV or GBP [39].  
Less usual options include stiripentol (STP), vigabatrin (VGB), felbamate (FLB) and clobazam 
(CLB) as they are usually used in difficult to treat generalised syndromes. STP and FLB are 
not even approved for focal seizures. Data on STP are mainly available in children but there is 
no conclusive evidence that it is effective in focal epilepsies [40]. VGB seems to be effective 
as adjunctive treatment in focal epilepsies but, as already mentioned, the use is burdened by 
the visual field problems [41]. Data on FLB in focal epilepsies are not conclusive but do not 
seem to support its use in this context [42]. Evidence on CLB is still limited but a small trial 
on 197 patients seems promising [43]. 
There is no clear evidence that one ASM is superior to another one as adjunctive treatment. A 
systematic review of 62 placebo controlled RCTs and 8 head-to-head RCTs including 14,272 
patients showed that differences among ASMs are of relatively small magnitude to allow a 
definitive conclusion about which drug has superior effectiveness.  TPM and LEV seem to be 
more efficacious, whereas GBP and TGB may be less efficacious. Withdrawal rates were 




3. DRUGS FOR ORPHAN INDICATIONS 
In 2017, everolimus was approved for the treatment of focal seizures in patients with Tuberous 
Sclerosis Complex (TSC). Everolimus belongs to a specific class of compounds called mTOR 
inhibitors [45]. Dysregulation of mTOR pathways has been implicated in tuberous sclerosis 
complex (TSC), focal cortical dysplasia (FCD), ganglioglioma and hemimegaloencephaly [46]. 
The efficacy of everolimus in TSC is based on a Phase III RCT showing that high-exposure 
everolimus (9-15 ng/mL) is associated with a median percentage reduction in seizure frequency 
of 39.6% as compared to 29.3% with low-exposure everolimus (3-7 ng/mL) and 14.9% with 
placebo [47]. The open label extension phase provided further data on the efficacy and safety 
of everolimus [48]. A study investigating the antiepileptic efficacy of everolimus in patients 
with Focal Cortical Dysplasia Type II and drug-resistant seizures is planned (NCT03198949) 
[45]. 
Cannabidiol (CBD) is currently licensed for the treatment of epilepsy in people with Lennox-
Gastaut and Dravet syndrome aged 2 or more. These syndromes cannot be considered focal 
epilepsies despite these patients can have focal seizures as part of the syndrome. Data on 
efficacy of CBD on focal seizures are more than scant and most of the data come from children 
[49]. 
 
4. NEW DRUG OPTIONS: CENOBAMATE 
Cenobamate (CNB) has been recently approved by U.S. Food and Drug Administration (FDA) 
for the treatment of focal seizures in the adults and it is awaiting approval from the European 
Medicine Agency (EMA). CNB inhibits the voltage-gated persistent component of the sodium 
currents and is an allosteric GABA(A) channel modulator in a non-benzodiazepine fashion 
[50]. It has demonstrated broad-spectrum efficacy in alternative preclinical models of epilepsy.  
CNB is available only as oral formulation and showed linear pharmacokinetics with long half-
life (30-76 hours) and steady-state attained after approximately two weeks supporting the once-
daily dosing [51]. There is no data on pharmacokinetics in subjects with liver impairment, 
while renal impairment may be associated with reduced clearance and 200 mg is the maximum 
recommended dose in this population [52]. CNB has some potential interactions with other 
ASMs because it decreases plasma concentrations of CYP2B6 and CYP3A substrates and 
increases plasma concentrations of CYP2C19 substrates. As a consequence, CNB can increase 
blood levels of PHT and desmethyl-CLB (the active metabolite of CLB) and can reduce blood 
levels of LTG and CBZ [52]. VPA, LEV and LCM seem to have no interactions with CMB. A 
Phase III, open-label, safety study of CNB in 1,339 patients showed that PHT and PB require 
a dose reduction ranging between 25% and 33% to maintain the same blood levels [53].  
Efficacy of CNB is based on Phase II and III studies. A Phase II RCT of 222 patients (age 18-
65) with focal epilepsy compared CNB 200 mg against placebo [54]. CNB was started at 50 
mg and increased by 50 mg increments every two weeks to a target dose of 200 mg, reached 
by 67% subjects. Responder rate (at least 50% seizure reduction) was 50.4% and seizure free 
rate 28.3% [54]. A Phase III RCT on 437 patients (age 18-70) with focal epilepsy compared 
placebo with CNB 100 mg, 200 mg and 400 mg showing responder rates of 25%, 40%, 56%, 
64% and seizure free rates of 1%, 4%, 11% and 21% for placebo, CNB 100 mg, 200 mg and 
400 mg respectively [55]. Data on seizure freedom have been considered particularly promising 
given that a systematic review of RCTs of ASMs reported seizure freedom rates up to 6.5% for 
previous ASMs [44]. A proof-of-concept study in a small sample of six patients showed also 
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promising therapeutic effect in photosensitive epilepsy for doses higher than 200 mg [56]. 
However, this would be relevant for generalised rather focal syndromes.  
Even though the results are statistically significant and very encouraging, it has to be 
acknowledged that some of the estimates have a very wide confidence interval, which does 
introduce uncertainty regarding the magnitude of the treatment effect over placebo, as 
suggested by a recent systematic review with meta-analysis [57]. 
Treatment-emergent adverse events (TEAEs) reported in >10% included somnolence 22.1%, 
dizziness 22.1%, headache 12.4%, nausea 11.5% and fatigue 10.6% [54]. The Phase III study 
reported TEAEs leading to discontinuation in 5% of patients in the placebo group, 10% for 
CNB 100 mg, 14% for CNB 200 mg and 20% for CNB 400 mg [55]. One serious case of drug 
reaction with eosinophilia and systemic symptoms (DRESS) occurred in the 200 mg CNB 
group but no deaths were reported [55]. This was not the only case of DRESS and two other 
cases were observed during previous development phases for a total of 3 cases, including one 
fatality, out of the  first  953 subjects  exposed  to CNB, leading to a frequency of 3 cases per 
1,000. Prevalence of DRESS with other ASMs seems to range between 1 per 5,000 and 1 per 
10,000 [58]. Concerns regarding an increased risk of DRESS with CNB led to a Phase III open 
label safety study which involved 1,339 patients [53]. CNB was started at 12.5 mg and 
increased with increments every 2 weeks to 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg. The 
most common TEAEs included somnolence in 28.1%, dizziness in 23.6%, and fatigue in 16.6% 
but no cases of DRESS were reported suggesting that a slow titration regime may limit such a 
risk [53].  
 
5. CONCLUSIONS 
Out of 17 drugs approved for focal seizures, 10 are also licensed for monotherapy, one has the 
orphan indication of focal seizures in TSC and two are rarely used given safety and tolerability 
issues. Level A evidence for initial monotherapy is available for LEV, PHT, LTG, CBZ-CR, 
ZNS, LCM, ESL with no robust data supporting that one drug is superior to the other is terms 
of efficacy. Safety and tolerability profile favour LEV and LTG for initial monotherapy 
especially in women of childbearing age and elderly.  
Data on adjunctive treatment are available for 13 drugs showing again no obvious difference 
in terms of efficacy while data on tolerability favour LEV, LTG, LCM and BRV. CNB is the 
latest drug approved for focal seizures with promising efficacy results, but patients need to be 
informed about the increased risk of DRESS syndrome. 
 
6. EXPERT OPINION 
Meta-analyses and systematic reviews published in the last few years have facilitated the 
recognition of knowledge gaps and information needed to provide evidence-based treatment 
decisions in people with epilepsy. Class 1 studies are now routinely available for new anti-
seizure medicines (ASMs) but randomised controlled trials have limitations in terms of 
duration of the follow up and outcome measures. For all drugs, outcome measures such as 
response rates or seizure free rates are based on a 12-week period at best. Data on sustained 
seizure freedom are needed and to have comparable results the ILAE definition of drug-
resistance can be considered the theoretical framework to develop meaningful outcome 
measures based on number of previously failed drug trials and duration of the observation.  
Regarding monotherapy of focal epilepsies, of the 10 drugs currently approved for focal 
seizures, there is a Level A of evidence based on Class 1 studies in more than half. There is, 
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however, no evidence that one drug is more effective than another one and safety, tolerability 
as well as pharmacoeconomic reasons would then become preponderant when choosing the 
most appropriate drug. Current data suggests that levetiracetam and lamotrigine are the best 
options when all these factors are considered especially in women of childbearing age or 
elderly.  
For the adjunctive treatment of focal epilepsies, the scenario is similar with no evidence that 
one drug is superior to the other and data on tolerability seem to favour levetiracetam, 
lamotrigine, lacosamide and brivaracetam. Of the currently 17 approved drugs, 13 are routinely 
used while vigabatrin and tiagabine, despite approved for the use in focal seizures, are very 
rarely prescribed due to safety concerns; everolimus, is approved only in patients with tuberous 
sclerosis complex while cenobamate has been just recently marketed. Cenobamate is the latest 
option approved for the treatment of focal seizures and seizure free rates seem to be remarkably 
promising as compared to other ASMs, but this is not based on head-to-head comparison. The 
lack of multiple formulations (e.g. liquid or intravenous), the long titration regime and the 
increased risk of drug reaction with eosinophilia and systemic symptoms (DRESS) represent 
potential limitations and further data will be needed.  
Data on the synergistic effect of specific combinations of ASMs are almost entirely non-
existent and the decision to combine two specific compounds is based entirely on the 
experience of the individual clinician. In focal epilepsy, there is only a single study suggesting 
that the combination lamotrigine and valproate is as effective as carbamazepine. Studies 
clarifying this point are urgently needed.  
Research into the pharmacological treatment of focal epilepsies in the next 5 years will need to 
move towards precision medicine and novel mechanisms of action given that available options 
have provided very similar results in terms of efficacy. Studies exploring potentially synergistic 
combinations are needed and they would have a strong impact on clinical practice. Head-to-
head comparison studies are needed to clarify differences among ASMs in terms of efficacy 
and tolerability, but outcome measures will need to consider the number of previously failed 
drugs and longer observation periods.  
 
7. ARTICLE HIGHLIGHTS 
• 17 drugs are currently licensed for the treatment of focal seizures 
• Level A of evidence for the initial monotherapy of focal seizures is available for 7 drugs 
with no difference in terms of efficacy 
• Data on adjunctive treatment is available for 13 drugs with no difference in terms of 
efficacy 
• Lamotrigine and levetiracetam represent the best options when efficacy safety and 
tolerability are considered 
• Evidence of specific drug combinations is non-existent and clinical practice is based on the 
experience of the individual clinician 
• Head-to-head comparison studies using appropriate outcome measures are needed    
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Table 1. Drug options for adults with focal epilepsy.  






Interactions with other anti-seizure medications (ASMs) 
Brivaracetam No 50-200 6-11 Blood levels reduced by enzyme-inducing ASMs; 
It increases carbamazepine 10,11 epoxide 
Cenobamate No 200-400 30-76 It increases blood levels of phenytoin, phenobarbital and desmethyl-clobazam; It reduces blood levels 
of lamotrigine and carbamazepine 
Carbamazepine Yes 400-2000 10-20 Blood levels reduced by enzyme-inducing ASMs and increased by vigabatrin; Carbamazepine 10,11 
epoxide levels increased by valproate and brivaracetam 
Eslicarbazepine Yes 800-1600 13-20 Licarbazepine concentrations reduced by enzyme inducing ASM 
Everolimus* No ¥5/m2 25-35 Blood levels reduced by enzyme-inducing ASMs; 
Gabapentin No 900-2700 5-9 None 
Lacosamide Yes 100-400 12-16 Blood levels reduced by enzyme-inducing ASMs; 
Levetiracetam Yes 1000-3000 6-8 Blood levels reduced by enzyme-inducing ASMs; 
Lamotrigine Yes 100-600 20-40 Blood levels increased by VPA and reduced by enzyme-inducing ASMs; 
Oxcarbazepine Yes 600-2400 7-12 Licarbazepine concentrations reduced by enzyme inducing ASM; It increases blood levels of 
phenytoin and phenobarbital 
Phenytoin Yes 300 7-42 Blood levels increased by topiramate and oxcarbazepine; Reduced by vigabatrin and valproate (free 
fraction)  
Perampanel No 6-12 50-130 Blood levels reduced by enzyme-inducing ASMs; 
Tiagabine No 16-56 5-9 Blood levels reduced by enzyme-inducing ASMs; 
Topiramate Yes 100-600 20-30 Blood levels reduced by enzyme-inducing ASMs; TPM can increase PHT blood levels 
Vigabatrin# No 1000-6000 4-7 It can decrease phenytoin levels 
Valproate Yes 600-2000 8-17 Blood levels reduced by enzyme-inducing ASMs and topiramate 
Zonisamide Yes 150-450 50-70 Blood levels reduced by enzyme-inducing ASMs; 
Mono= monotherapy indication; Enzyme inducing ASMs= phenytoin, phenobarbital, primidone, carbamazepine 
*in patients Tuberous Sclerosis Complex 
¥starting dose 5mg/m2 without CYP3A4/PgP inducer; 8 mg/m2 with CYP3A4/PgP inducer. Increase 2 mg/d to blood levels 5-7 ng/mL (max 15 
ng/mL) 






Table 2. Meta-analytic evidence on efficacy and tolerability of antiseizure medications as adjunctive treatment.  
ASMs Dose 
mg 
N patient Max duration observation  
(weeks) 
RR ≥50% seizure reduction  
(95%CI) 
RR treatment withdrawal (95%CI) Ref 
Brivaracetam 10-600 2411 16 1.81 (1.53-2.14) 1.27 (0.94-1.74) [59] 
Eslicarbazepine 800-1600 1799 18 1.71 (1.42-2.05) 2.66 (1.42-4.96) [60] 
Gabapentin 600-1800 2607 14 1.89 (1.40-2.55) 1.05 (0.74-1.49) [36] 
Lacosamide 200-600 1311 26 1.70 (1.38-2.10) 1.88 (1.40-2.52) [34] 
Levetiracetam 1000-3000 A=2159 
C=296 
24 2.37 (2.02-2.78) 1.11 (0.89-1.40) [31] 
Lamotrigine 75-600 A=1569 
C=199 
24 1.80 (1.45- 2.23) 1.11 (0.91-137) [30] 
















Pregabalin 150-600 3327 17 2.28 (1.52-3.42) 1.35 (1.11-1.65) [39] 
Tiagabine 16-56 948 22 3.16 (1.97-5.07) 1.81 (1.25-2.62) [37] 
Topiramate 50-600 1650 19 2.71 (2.05-3.59) 2.37 (1.66-3.37) [61] 
Vigabatrin 1000-6000 756 36 2.60 (1.87-3.63) 2.86 (1.25-6.55) [62] 
Zonisamide 100 -500 1636 18 1.86 (1.60-2.17) 1.44 (1.08-1.93) [63] 
A=adult; C=children 
 
